Aptra Synthesis Clopidogrel Aptra Synthesis Clopidogrel

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Medicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicure Announces AGGRASTAT\u00ae Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"AcuteBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation for Clopidogrel that Received IND Approval","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USV Launches Roseday CV at a Patient-Centric Price for Indian Cardiac Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Clopidogrel Bisulfate

    Menu

    Clopidogrel Bisulfate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              USV Private Limited

              Contact Supplier
              • Development Update
              Virtual BoothUSV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              USV Launches Roseday CV at a Patient-Centric Price for Indian Cardiac Patients

              Details:

              Roseday CV (rosuvastatin + clopidogrel) is a fixed dose combination which is approved for the treatment of cardiac diseases like heart attack, angina & stroke.

              Lead Product(s): Rosuvastatin,Clopidogrel

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Roseday CV

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 24, 2023

              USV Private Limited

              CPhI Worldwide, Milan

              Booth #10F41

              envelop Contact Supplier

              Ascendia Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation for Clopidogrel that Received IND Approval

              Details:

              ASD-002 (clopidogrel) being developed by EmulSol nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval for Acute Coronary Syndrome.

              Lead Product(s): Clopidogrel

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: ASD-002

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: AcuteBio

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Medicure

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports

              Details:

              Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves hypoxemia.

              Lead Product(s): Tirofiban,Clopidogrel,Aspirin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Aggrastat

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              DRL Clopidogrel
              Octavius Clopidogrel
              Close
              4
              Post Enquiry
              POST ENQUIRY